Bacteraemic and non-bacteraemic/urinary antigen-positive pneumococcal community-acquired pneumonia compared

被引:0
|
作者
S. P. van Mens
A. M. M. van Deursen
S. C. de Greeff
H. E. de Melker
L. M. Schouls
A. van der Ende
M. J. M. Bonten
E. A. M. Sanders
B. J. M. Vlaminckx
机构
[1] St. Antonius Hospital,Department of Medical Microbiology and Immunology
[2] University Medical Center Utrecht,Medical Microbiology
[3] Linnaeus Institute,Paediatric Immunology and Infectious Diseases
[4] Wilhelmina Children’s Hospital,Medical Microbiology
[5] National Institute for Public Health and the Environment,Netherlands Reference Laboratory for Bacterial Meningitis
[6] Academic Medical Center Amsterdam,undefined
[7] Academic Medical Center Amsterdam,undefined
关键词
Blood Culture; Invasive Pneumococcal Disease; Pneumococcal Pneumonia; Immunocompromising Condition; Heart Valve Disease;
D O I
暂无
中图分类号
学科分类号
摘要
The diagnosis of invasive pneumococcal pneumonia is based mainly on bacteraemia. Episodes without bacteraemia, but with a positive urinary antigen test (UAT), are considered non-invasive. We determined differences in outcome between patients with bacteraemic and non-bacteraemic/UAT-positive pneumococcal community-acquired pneumonia (CAP). Adult patients with clinical and radiological evidence of CAP with blood cultures and UAT tests performed at presentation in three Dutch laboratories between June 2008 and May 2010 were included. Clinical characteristics were retrospectively extracted from hospital records. Overall, 168 patients had non-bacteraemic/UAT-positive pneumococcal CAP and 123 had bacteraemic pneumococcal CAP. The day-30 mortality was 9 % and 13 % for non-bacteraemic/UAT-positive and bacteraemic pneumococcal CAP patients, respectively [risk difference −4 %, 95 % confidence interval (CI) −11 % to +3 %, p = 0.28]. In a multivariable logistic regression model, age ≥65 years, admission to the intensive care unit/coronary care unit (ICU/CCU) and presence of an immunocompromising condition were associated with day-30 mortality. A non-significant association with mortality was found for bacteraemia [odds ratio (OR) 2.21, 95 % CI 0.94–5.21, p = 0.07). No such trend was found for UAT positivity. The median lengths of hospital stay were 8 [interquartile range (IQR) 5–14] and 10 (IQR 6–18) days for non-bacteraemic/UAT-positive and bacteraemic pneumococcal CAP patients, respectively (p = 0.05). As compared to non-bacteraemic/UAT-positive pneumococcal CAP, bacteraemic pneumococcal CAP has a stronger association with day-30 mortality.
引用
收藏
页码:115 / 122
页数:7
相关论文
共 50 条
  • [41] Characteristics of patients with community-acquired pneumococcal pneumonia
    Padiglione, AA
    Willis, J
    Bailey, M
    Fairley, CK
    MEDICAL JOURNAL OF AUSTRALIA, 1999, 170 (04) : 165 - 167
  • [42] Pneumococcal virulence factors in community-acquired pneumonia
    Feldman, Charles
    Anderson, Ronald
    CURRENT OPINION IN PULMONARY MEDICINE, 2020, 26 (03) : 222 - 231
  • [43] Controversies in the treatment of pneumococcal community-acquired pneumonia
    Feldman, Charles
    Anderson, Ronald
    FUTURE MICROBIOLOGY, 2006, 1 (03) : 271 - 281
  • [44] Influence of comorbidities on pneumococcal community-acquired pneumonia
    Polverino, Eva
    Cilloniz, Catia
    Gabarrus, Albert
    Amaro, Rosanel
    Domingo, Rebeca
    Sialer, Salvador
    Sellares, Jacobo
    Torresi, Antoni
    Polverino, Eva
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [45] Pneumococcal vaccines and the prevention of community-acquired pneumonia
    Esposito, Susanna
    Principi, Nicola
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2015, 32 : 124 - 129
  • [46] Evaluation of Sofia Fluorescent immunoassay analyzer for pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia
    Vicente, Diego
    Lopez-Olaizola, Maddi
    de la Caba, Idoia
    Cilla, Gustavo
    JOURNAL OF MICROBIOLOGICAL METHODS, 2017, 141 : 25 - 27
  • [47] Derivation and external validation of a prediction model for pneumococcal urinary antigen test positivity in patients with community-acquired pneumonia
    Kim, Priscilla
    Rothberg, Michael B.
    Nowacki, Amy S.
    Yu, Pei-Chun
    Gugliotti, David
    Deshpande, Abhishek
    ANTIMICROBIAL STEWARDSHIP & HEALTHCARE EPIDEMIOLOGY, 2023, 3 (01):
  • [48] De-escalation therapy among bacteraemic patients with community-acquired pneumonia (vol 21, 936.e11, 2015)
    Carugati, M.
    Franzetti, F.
    Wiemken, T.
    Kelley, R. R.
    Peyrani, P.
    Blasi, F.
    Ramirez, J.
    Aliberti, S.
    CLINICAL MICROBIOLOGY AND INFECTION, 2015, 21 (12) : E87 - E87
  • [49] Usefulness of Urinary Pneumococcal Antigen Testing in Patients with Community Acquired Pneumonia.
    Biswas, N.
    Cann, K.
    Shahidi, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [50] DETECTING PNEUMOCOCCAL ANTIGEN IN COMMUNITY ACQUIRED PNEUMONIA
    SMYTH, EG
    POMEROY, L
    BRITISH MEDICAL JOURNAL, 1987, 295 (6610): : 1415 - 1415